Dynamic Light Scattering Ocular Measurement in the Detection of Dementia
Launched by MD STEM CELLS · Sep 23, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to detect dementia by taking a noninvasive measurement from a patient's eye. Researchers want to find out if there are noticeable differences in these eye measurements between people who have dementia, including Alzheimer's disease, and those who do not. This could help doctors diagnose dementia more easily and quickly in the future.
To participate in this study, you need to be between the ages of 65 and 74, and able to follow instructions during eye exams. It’s important that you can understand the study and give your consent to participate. If you are pregnant or not in stable health, you won't be eligible. Participants will undergo eye examinations, but these will be done in a gentle and noninvasive way. This trial is currently looking for volunteers, so if you're interested or know someone who might be, it could be a valuable opportunity to contribute to dementia research.
Gender
ALL
Eligibility criteria
- • 1. All patients must be capable of an adequate ophthalmic evaluation and testing. This includes the ability to cooperate with the exam, sufficiently clear media (cornea, lens, vitreous) and sufficient pupillary dilation.
- • 2. Patients must be capable of providing informed consent.
- • 3. Patients who are not medically stable or who may be at significant risk to their health will not be eligible.
- • 4. Women of child bearing age must not be pregnant at the time of examination.
About Md Stem Cells
MD Stem Cells is a leading clinical trial sponsor dedicated to advancing regenerative medicine through innovative stem cell therapies. Committed to rigorous scientific research and ethical practices, the organization focuses on developing groundbreaking treatments for various conditions, leveraging its expertise in cellular biology and patient-centered care. By collaborating with healthcare professionals and institutions, MD Stem Cells aims to translate cutting-edge research into effective clinical applications, ultimately improving patient outcomes and quality of life. Their commitment to safety, efficacy, and transparency underscores their role as a trusted partner in the evolving landscape of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Coconut Creek, Florida, United States
Patients applied
Trial Officials
Jeffrey N Weiss, MD
Principal Investigator
The Healing Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported